Richard Cunningham
Directeur Général chez TYME TECHNOLOGIES, INC.
Profil
Richard Anthony Cunningham is currently the President, Chief Executive Officer & Director at Icagen-T, Inc. He is also the Chief Executive Officer & Director at Anebulo Pharmaceuticals, Inc. and the Chief Executive Officer at Tyme Technologies, Inc. Previously, he served as the President, Chief Executive Officer & Director at Icagen, Inc. from 2014 to 2020.
Postes actifs de Richard Cunningham
| Sociétés | Poste | Début |
|---|---|---|
| TYME TECHNOLOGIES, INC. | Directeur Général | 24/11/2020 |
| ANEBULO PHARMACEUTICALS, INC. | Directeur Général | 05/10/2023 |
Icagen-T, Inc.
 Icagen-T, Inc. BiotechnologyHealth Technology Icagen-T, Inc. engages in development of pharmaceutical drugs. The company is headquartered in Oro Valley, AZ. | Directeur Général | - |
Anciens postes connus de Richard Cunningham
| Sociétés | Poste | Fin |
|---|---|---|
Icagen, Inc.
 Icagen, Inc. Medical SpecialtiesHealth Technology Icagen, Inc. engages in the development of pharmaceutical and drug discovery instruments. It offers chemistry, biology, and ion channels and transporters. The company was founded by Benjamin P. Warner and Frank Jeremiel Zimmerman in 1992 and is headquartered in Durham, NC. | Directeur Général | 01/11/2020 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ANEBULO PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Icagen, Inc.
Icagen, Inc. Medical SpecialtiesHealth Technology Icagen, Inc. engages in the development of pharmaceutical and drug discovery instruments. It offers chemistry, biology, and ion channels and transporters. The company was founded by Benjamin P. Warner and Frank Jeremiel Zimmerman in 1992 and is headquartered in Durham, NC. | Health Technology |
Tyme Technologies, Inc.
 Tyme Technologies, Inc. Pharmaceuticals: MajorHealth Technology Tyme Technologies, Inc. operates as a biotechnology company, which engages in the development and commercialization of cancer therapies. It offers a clinical program named SM-88 which is a novel, oral, and monotherapy investigational agent that aims to disrupt the cancer cell's protein synthesis. The company was founded by Steve Hoffman and Michael Demurjian on November 22, 2011 and is headquartered in Bedminster, NJ. | Health Technology |
Icagen-T, Inc.
Icagen-T, Inc. BiotechnologyHealth Technology Icagen-T, Inc. engages in development of pharmaceutical drugs. The company is headquartered in Oro Valley, AZ. | Health Technology |
